Preferred Label : Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211;
NCIt synonyms : Allogeneic shRNA-based Anti-BCMA CAR-T Cells CYAD-211;
NCIt definition : A preparation of human allogeneic, 'off-the-shelf' (OTS), non-gene edited T-lymphocytes
that are engineered to co-express a chimeric antigen receptor (CAR) specific for the
tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis
factor receptor superfamily member 17; TNFRSF17) and a single short hairpin RNA (shRNA)
that disrupts the expression of the CD3zeta component of the T-cell receptor (TCR),
with potential immunostimulating and antineoplastic activities. Upon administration,
the allogeneic shRNA-based anti-BCMA CAR T-cells CYAD-211 recognize and bind to BCMA-overexpressing
tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing
of BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing
ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis
factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival.
BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma
cells. The downregulation of the expression of the TCR CD3zeta subunit by shRNA prevents
the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.;
Molecule name : CYAD-211; CYAD 211;
NCI Metathesaurus CUI : CL1642937;
Origin ID : C176885;
UMLS CUI : C5447497;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
